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Assessment of Objective Responses Using Volumetric
Evaluation in Advanced Thymic Malignancies and
Metastatic Non-small Cell Lung Cancer
Jeremy Force, MA,* Arun Rajan, MD,* Eva Dombi, MD,† Seth M. Steinberg, PhD,‡
and Giuseppe Giaccone, MD, PhD*
Introduction: Measurement of tumor response by standard re-
sponse criteria is challenging in thymic malignancies, especially
when the pleura is involved, as it often is in stage IV disease. In this
study, we aimed to determine the effectiveness of volumetric re-
sponse evaluation criteria in solid tumors (volumetrics) for evaluat-
ing response in patients with thymic malignancies treated on a phase
II study of belinostat.
Methods: We evaluated the tumor responses of 25 patients with
thymic cancer using computed tomography-based RECIST, World
Health Organization (WHO), modified RECIST, and volumetrics.
As a control, we assessed 37 patients with non-small cell lung cancer
(NSCLC) with RECIST and volumetrics.
Results: Agreement analyses in 23 patients with thymic cancer at the
time of RECIST-determined progressive disease (PD) compared volu-
metrics with RECIST, modified RECIST, and WHO criteria. Use of
volumetrics was associated with 22% discordance compared with
RECIST, 15% versus modified RECIST, and 22% versus WHO criteria.
Volumetrics revealed PD 72 days earlier than RECIST (p  0.016). In
another cohort of 35 patients with NSCLC, there was 9% discordance
between volumetrics and RECIST at the time of PD. Volumetrics demon-
strated PD 32 days earlier than RECIST in NSCLC (p  0.0078).
Conclusions: Our study suggests that volumetrics might improve
detection of PD. Prospective evaluation of this technique in a larger
series of patients with thymic malignancies will be required.
Key Words: Thymic malignancy, Thymic cancer, Thymoma,
Three-dimensional, Volumetric, RECIST, Non-small cell lung can-
cer, Computed tomography.
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The World Health Organization (WHO) and Miller et al.1,2developed criteria in the late 1970s and early 1980s to
address the need for a common language to ensure consistent
and objective reporting of results of treated cancer patients
with solid tumors. More recently, the RECIST were devel-
oped, which make use of unidimensional tumor measure-
ments, in contrast to the bidimensional measurements of the
WHO criteria. An updated version of the original RECIST
criteria has very recently been introduced (RECIST 1.1).3,4
RECIST 1.1 is now the gold standard for measuring disease
burden in solid tumors in clinical trials. Nevertheless, there
are limitations in measuring tumors using only one dimen-
sion, which are dictated by the shape of the tumor and the
sharpness by which edges can be defined on conventional
imaging.
Thymic cancers are rare neoplasms accounting for 0.2
to 1.5% of all cancers.5 It is not uncommon for these tumors
to metastasize to the pleural cavity.6 Given the anatomy of the
thoracic cavity, metastases to the pleura often seem as cur-
vilinear plaques on computed tomography (CT). These
plaques are difficult to measure when using RECIST (Figure
1), for which only one CT slice of the target lesion along the
longest diameter is taken, which may not accurately reflect
their noncylindrical tumor growth pattern.
Since the existence of RECIST, there has been much
debate about what type of tumor size assessment is the most
informative. Recently, various methods of three-dimensional
measurement criteria to evaluate cancer target lesions by CT
have been under assessment including mathematical formu-
lae,7 modified RECIST,8,9 and computer-assisted sys-
tems10–12 to estimate total tumor volume. These assessment
methods have been investigated in various tumor types re-
sulting in conflicting conclusions. Tumor volume can be
calculated from RECIST-based measurements assuming that
the tumor mass is cylindrical in nature. Nevertheless, many
tumor lesions in various cancer types do not seem as cylin-
drical masses on CT.
Three-dimensional measurements have been validated
for the growth of plexiform neurofibromas in patients with
neurofibromatosis I using magnetic resonance imaging
(MRI).13 In addition, preoperative three-dimensional tumor
volumes less than 51 ml have been associated with longer
progression-free survival (PFS) in malignant pleural meso-
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thelioma.14 On the other hand, measurement of three-dimen-
sional tumor volume was not demonstrated to have any
prognostic significance compared with RECIST in patients
with rhabdomyosarcoma treated with chemotherapy.15 In
addition, no difference in PFS was noted in a comparison of
RECIST against bi-dimensional and three-dimensional tumor
response in adults with high-grade gliomas.16
We performed a retrospective study of patients with
advanced thymic cancers enrolled in a phase II clinical trial
treated with the histone deacetylase inhibitor, belinostat,
aimed to investigate whether the clinical outcome of these
patients would differ based on the method of evaluation used;
i.e., RECIST, WHO, modified RECIST, and what we have
termed volumetric RECIST (volumetrics). We also analyzed
a separate cohort of patients with metastatic non-small cell
lung cancer (NSCLC) enrolled in a phase II clinical trial of
the single-agent multikinase inhibitor, sorafenib, where
RECIST is the standard measurement method, as a control
group to determine if there were any differences in objective
response when using volumetrics or RECIST.
PATIENTS AND METHODS
Measurement Methods
Tumor measurements were determined through axial
CT scans or MRI scans when appropriate. Only one MRI was
used in this study to follow a patient with thymic cancer who
had metastatic disease solely in the liver. In addition to the
MRI scans, subsequent restaging CT scans were performed to
assess for new lesions in this patient. Tumor measurements in
this patient were based on lesions determined by MRI scans.
Baseline scans were read, and the five largest target lesions
measuring more than 1 cm were chosen and measured using
RECIST. All other target lesion measurements in this study
were made retrospectively. Thymic cancer tumor burden was
evaluated using RECIST,3 modified RECIST,8 and WHO
criteria.1,17 In addition, given the similarity in appearance on
CT scans of metastatic pleural deposits of thymic tumors and
malignant pleural mesothelioma, we choose to use three-
dimensional volumetric criteria described by Ak et al.18
Assuming one is measuring a spherical lesion, mathe-
matical formulae reveal that RECIST-defined partial response
(PR) of 30% in the longest diameter and WHO-defined 50%
decrease in two-dimensional measurements both equal to a
65% decrease in three-dimensional measurement. In addition,
for a spherical lesion, the RECIST-defined disease progres-
sion of 20% increase in the longest diameter equals 77%
increase in volume, and the WHO-defined 25% increase in
two-dimensional measurements equals 40% increase in vol-
ume (Table 1).12,18 Using receiver operating characteristic
analysis, Ak et al.18 showed that a15% increase and50%
decrease in tumor volume were sensitive in detecting pro-
gression and response, respectively, and a significant corre-
lation was demonstrated between median survival and re-
sponse. These measurement cutoff values of 15% increase
and50% decrease in three-dimensional tumor volume were
thus shown to be sensitive in a nonspherical growing tumor
and justified our use of these criteria.
Tumor volume was measured using MEDx software
(Medical Numerics Inc., Germantown, MD), which calcu-
lates tumor volume by detecting pixels above 500
Hounsfield units from all CT slices containing manually
outlined tumor lesions. A complete response (CR) was de-
fined the same manner as RECIST.3 Confirmed PR was
defined as a 50% decrease in the sum of volumetric mea-
surements and having continuously stable nontarget lesions
from the baseline in at least two consecutive CT scans.
Progressive disease (PD) was defined as a 15% increase in
tumor volume of target lesions, or unequivocal increase in
nontarget lesions, and/or appearance of new lesions observed
from the smallest measurement.18 Patients were considered to
have stable disease if their volumetric measurements were
more than PR and less than PD.
Patients and Study Design
We analyzed tumor burden in 25 consecutive patients
with advanced thymoma and thymic carcinoma enrolled in a
phase II clinical trial treated with a histone deacetylase
inhibitor, belinostat, at our institution.19 Tumor burden was
FIGURE 1. Patients with metastatic thymoma target lesion
measured with RECIST and volumetrics at baseline and fol-
low-up restaging CT scans. CT, computed tomography.
TABLE 1. Comparison of Tumor Volume Percent Changes
in RECIST (Unidimensional), WHO (Bidimensional), and
Volumetrics (Three Dimensional) Relative to One Another
% Change in Size of Spherical Tumors
1D RECIST (%) 2D WHO (%) 3D Volumetrics (%)
6 13 20
12 25 40
20 44 73
WHO, World Health Organization; 1D, unidimensional; 2D, bidimensional; 3D,
three dimensional.
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prospectively evaluated by RECIST. We retrospectively an-
alyzed these patients’ tumor burden using modified RECIST,
WHO criteria, and volumetrics at baseline and at every
restaging time point. For agreement analyses in the thymic
cancer cohort, we compared volumetrics against other mea-
surement criteria mentioned above.
Initially, we analyzed the data for agreement at the time
of RECIST-determined best response. We then assessed for
agreement among the target lesion measurements alone at the
time of RECIST-designated PD. We also performed an agree-
ment analysis using the entire criteria of RECIST (target
lesions, nontarget lesions, and new lesions) at the time of PD.
If disagreement was observed between volumetrics and
RECIST at the time of RECIST-designated PD, we deter-
mined which set of criteria revealed progression earlier. In
addition, overall survival beginning at the time of either
volumetrics or RECIST date of progression to their date of
death or date last known alive was assessed in those patients
who had progressed by either of the two measurement crite-
ria, respectively.
Patient characteristics in the advanced thymic cancer
cohort are presented in Table 2. At the time of writing this
report, two patients were on study. All 25 patients were
evaluated for best response, including the two patients on
study. As PD data points could not be determined until
patients came off study, we did not include these two patients
in the PD analyses.
We chose patients with NSCLC as a control group as
imaging studies were readily available, and RECIST is the
standard measurement criteria. We evaluated tumor burden in
37 consecutive patients with metastatic NSCLC in a single-
center phase II clinical trial treated with the multikinase
inhibitor, sorafenib.20 Tumor burden was evaluated prospec-
tively with RECIST. We retrospectively analyzed these pa-
tients’ tumor burden with volumetrics at baseline and every
restaging time point until they came off study.
All agreement analyses in the NSCLC cohort were a
comparison of volumetrics against RECIST. Evaluation of
agreement, progression, and survival in the NSCLC cohort
occurred precisely in the same manner as the thymic
cancer cohort.
Patient characteristics in the metastatic NSCLC cohort
are depicted in Table 2. At the time of writing this report, two
patients were on study. All 37 patients with metastatic
NSCLC were evaluated for best response, including the two
patients on study. As PD information could not be determined
until patients came off study, we did not include these two
patients who remained on study in our PD analyses.
Statistical Methods
A McNemar’s test for paired categorical data was used
to determine the degree of the agreement between the various
measurement methods with respect to their response classi-
fication when compared together. A small two-tailed p-value
(0.05) would indicate that there was a significant difference
toward disagreement in one direction or the other when the
two methods showed discrepant results. A Wilcoxon signed
rank test was used to determine if one method detected
disease progression earlier than the other method in the cases
in which the two methods detected progression. The proba-
bility of survival or PFS as a function of time was determined
by the Kaplan-Meier method. A Cox proportional hazards
model was used, with the time of PD by either volumetrics or
RECIST criteria as a time-varying covariate, to determine if
the classification of progression by either method was asso-
ciated with the probability of survival. All p-values are
two-tailed and presented without any adjustment for multiple
comparisons.
RESULTS
Tumor Response in Advanced Thymic
Neoplasms
Initially, we identified the date of best response as
determined by RECIST, and then compared the extent of
agreement in declaring PD or other than PD at the
RECIST-designated best response date. We used volumetrics
as the comparator arm at this time point and evaluated it
against RECIST, modified RECIST, and WHO criteria in 25
patients with metastatic thymic cancer treated with single-
TABLE 2. Patient Characteristics
Characteristics
Number of
Patients (%)
Characteristics of patient with thymic cancer
Age (yr)
Median 53
Range 23–72
Sex
Male 15 (60)
Female 10 (40)
Ethnicity
White 22 (88)
African American 2 (8)
Asian 1 (4)
Histopathology
Thymoma 14 (56)
Thymic carcinoma 11 (44)
Characteristics of patient with non-small
cell lung cancer
Age (yr)
Median 63
Range 30–85
Sex
Male 18 (49)
Female 19 (51)
Ethnicity
White 25 (68)
African American 5 (13)
Asian 4 (11)
Hispanic 3 (8)
Histopathology
Adenocarcinoma 31 (84)
Squamous cell carcinoma 3 (8)
Poorly differentiate carcinoma 2 (5)
Large cell neuroendocrine 1 (3)
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agent belinostat. Compared with volumetrics, 56% of com-
parisons were not concordant with the findings from
RECIST, 45% were not concordant with modified
RECIST, and 52% were not concordant with WHO crite-
ria. In each case, the disagreements tended to identify
significantly greater PD outcomes with volumetrics as
opposed to RECIST (p  0.0001), modified RECIST (p 
0.002), or WHO criteria (p  0.023; Table 3). At the time
of best response as determined by RECIST, volumetrics
revealed that overall tumor burden was increasing in 14 of
25 (56%) patients. This suggested that the patient would
have been deemed to have PD at an earlier time point
and/or have a worse disease response if volumetrics were
used instead of RECIST.
In addition, we studied the target lesions alone at the
time of RECIST-designated disease progression and exam-
ined the agreement of volumetrics to RECIST, modified
RECIST, and WHO target lesions in the 23 patients with
metastatic thymic cancer who came off study. Compared
with volumetrics, 48% of comparisons were not concord-
ant with the findings from RECIST, 35% were not concordant
with modified RECIST, and 44% were not concordant with
WHO criteria. Nevertheless, in each case, the disagreements
tended to identify greater PD outcomes with volumetrics as
opposed to RECIST (p  0.001), modified RECIST (p 
0.016), or WHO criteria (p  0.11; Table 4). Volumetrics
target lesions alone detected disease progression in 11 cases
when RECIST target lesions alone demonstrated these same
patients to have stable disease or better. In other words,
RECIST-designated target lesions alone were less likely to
detect disease progression compared with volumetrics target
lesions alone when the patient had PD.
Finally, we analyzed the same 23 patients using the
entire criteria (target lesions, nontarget lesions, and new
lesions) of RECIST at the RECIST-determined time of pro-
gression and compared volumetrics against RECIST, modi-
fied RECIST, and WHO criteria for differences in agreement.
In this case, there were fewer discrepant cases because seven
patients were deemed PD by unequivocal increase in nontar-
get lesions or appearance of new lesions. Compared with
volumetrics, 22% of comparisons were not concordant
with the findings from RECIST, 15% were not concor-
dant with modified RECIST, and 22% were not concordant
with WHO criteria. In this setting, the disagreements tended
to identify relatively fewer additional PD outcomes with
volumetrics as opposed to RECIST (p  0.063), modified
RECIST (p  0.25), or WHO criteria (p  1.00; Table 5). In
addition, volumetrics identified PD an average of 72 days
earlier than RECIST when considering all lesions in the cases
in which both methods identified PD (p  0.0156). Thus,
TABLE 3. Agreement Analyses Determined by McNemar’s
Test in Advanced Thymic Cancers Comparing Volumetrics
Against RECIST, Modified RECIST, and WHO Criteria and
Volumetrics Compared with RECIST in Metastatic NSCLC at
the Time of RECIST-Designated Best Response
Frequency CR/PR/SD PD Total
RECIST
Volumetrics CR/PR/SD 8 0 8
PD 14a 3 17
Total 22 3 25
p  0.0001
Modified RECIST
Volumetrics CR/PR/SD 8 0 8
PD 10a 4 14
Total 18 4 22
p  0.002
WHO
Volumetrics CR/PR/SD 6 2a 8
PD 11a 6 17
Total 17 8 25
p  0.023
RECIST
Volumetrics CR/PR/SD 14 1a 15
PD 9a 11 20
Total 23 12 35
p  0.0215
p-value less than 0.05 indicates the two methods were not consistent with one
another.
Values in bold represent agreement.
a Disagreement.
CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease; NSCLC, non-small cell lung carcinoma; WHO, World Health Organization.
TABLE 4. Agreement Analyses Determined by McNemar’s
Test in Advanced Thymic Cancers Comparing Volumetrics
Against RECIST, Modified RECIST, and WHO Criteria and
Volumetrics Compared with RECIST in Metastatic NSCLC of
the Target Lesions Alone at the Time of RECIST-Designated
Progressive Disease
Frequency CR/PR/SD PD Total
RECIST
Volumetrics CR/PR/SD 4 0 4
PD 11a 8 19
Total 15 8 23
p  0.001
Modified RECIST
Volumetrics CR/PR/SD 4 0 4
PD 7a 9 16
Total 11 9 20
p  0.0156
WHO
Volumetrics CR/PR/SD 2 2a 4
PD 8a 11 19
Total 10 13 23
p  0.11
RECIST
Volumetrics CR/PR/SD 3 1a 4
PD 10a 19 29
Total 13 20 33
p  0.0117
p less than 0.05 indicates the two methods were not consistent with one another.
Bolded values represent agreement.
a Disagreement.
CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease; NSCLC, non-small cell lung carcinoma; WHO, World Health Organization.
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RECIST and volumetrics disagreed on disease progression
classification in 22% of cases, and volumetrics detected
disease progression significantly earlier than RECIST.
Progression by RECIST and volumetrics occurred in 15
and 20 of the 23 patients with thymic cancer, respectively.
The remaining eight patients were taken off study secondary to
clinical progression from pain (n  6) and voluntary removal
from the clinical trial (n  2). In these eight cases, RECIST
never determined the patients as having PD, whereas volumet-
rics deemed them as PD 62.5% (5/8) of the time.
When survival probabilities were calculated starting
from the date of progression by either method, the median
survival from date of volumetric progression was 12.5
months, whereas it was 9.3 months from date of RECIST
progression (Figures 2A, B). As there are different patients in
these two groups, formal comparison of survival times be-
tween these groups would not be appropriate.
Tumor Response in Metastatic NSCLC
We evaluated patients with NSCLC as a control group
because RECIST is the current gold standard measurement
method. This cohort was evaluated in a similar sequence to
the thymic cancer cohort, although only comparisons of
volumetrics against RECIST were assessed as modified
RECIST has not been validated in NSCLC and the WHO
criteria have been shown to be no better than RECIST.8 At
the time of RECIST-determined best response, 29% of sub-
jects had a disagreement noted between the two criteria, with
classifications favoring detection of progression by volumet-
rics (p  0.0215; Table 3). Assessment of the target lesions
alone at the time of RECIST-designated PD also revealed a
33% disagreement between the two methods and a large
tendency toward finding more progressions by volumetrics
(p  0.0117; Table 4). Nevertheless, 9% disagreement was
noted when the entire criteria (target lesions, nontarget le-
sions, and new lesions) were assessed between RECIST and
volumetrics at the time of RECIST-designated PD, and only
three discrepant cases were found—all classified as PD by
volumetrics (p  0.625; Table 5). Disease progression was
also demonstrated to occur significantly earlier by volumet-
rics by an average of 32 days (p  0.0078). These results
identified that there was no difference when using volumet-
rics or RECIST for determining whether there was disease
progression or not in patients with metastatic NSCLC, even
though volumetrics identified patients as having PD signifi-
cantly earlier than RECIST.
Restricted to the patients who progressed by either
RECIST or volumetrics in each case, we determined that
there was a median overall survival of 8.7 months from the
date of volumetrics progression compared with 8.8 months
from the date of RECIST progression (Figures 2C, D). To
evaluate if the time of determining progression could some-
how impact the probability of survival, a Cox proportional
hazards analysis was undertaken using the progression by
RECIST as a time-varying covariate. The impact of having a
progression determined by the RECIST criteria on survival
had an associated p-value of 0.14. Thus, there was no signif-
icant evidence that having progression, as determined by
RECIST, or not, as a function of when it was noted to occur,
has any impact on the overall survival of the patient. Because
of the fact that both patients who did not progress by volu-
metrics remain alive, the impact of this parameter could not
be properly estimated.
DISCUSSION
Two main findings stand out from our analyses. First,
volumetrics tended to identify PD more often than RECIST in
advanced thymic cancers but not in metastatic NSCLC. Second,
volumetrics deemed patients to have PD earlier than RECIST in
thymic cancers and NSCLC. Thus, it seems that three-dimen-
sional measurement criteria (volumetrics) may reveal disease
progression in patients demonstrating clinical or radiological
progression more often than unidimensional criteria (RECIST)
in thymic cancers but not in NSCLC.
Thymomas are slow growing tumors, and these patients
can live many years with their disease. Moreover, tumor
deposits in most patients with advanced thymic malignancies
are not spherical in shape, and when imaged by CT they
appear as curvilinear plaques within the pleural cavity. In
addition, volumetrics seems to identify PD more often and
detects it earlier when compared with RECIST. Given this
information, when the patient’s slow growing, nonspherical
TABLE 5. Agreement Analyses Determined by McNemar’s
Test in Advanced Thymic Cancers Comparing Volumetrics
Against RECIST, Modified RECIST, and WHO Criteria and
Volumetrics Compared with RECIST in Metastatic NSCLC of
the Entire Criteria (Target Lesions, Nontarget Lesions, and
New Lesions) at the Time of RECIST-Designated Progressive
Disease
Frequency CR/PR/SD PD Total
RECIST
Volumetrics CR/PR/SD 3 0 3
PD 5a 15 20
Total 8 15 23
p  0.0625
Modified RECIST
Volumetrics CR/PR/SD 3 0 3
PD 3a 14 17
Total 6 14 20
p  0.25
WHO
Volumetrics CR/PR/SD 1 2a 3
PD 3a 17 20
Total 4 19 23
p  1.00
RECIST
Volumetrics CR/PR/SD 0 0a 0
PD 3a 30 33
Total 3 30 33
p  0.25
p less than 0.05 indicates that the two methods were not consistent with one another.
Bolded values represent agreement.
a Disagreement.
CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease; NSCLC, non-small cell lung carcinoma; WHO, World Health Organization.
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disease burden is increasing, we feel that the use of volumet-
rics may aid clinicians considering alternative therapeutic
strategies at an earlier time point.
In addition, our data suggest that thymic malignancies
may be treated with potentially suboptimal therapy for a
longer duration if RECIST is used for assessment of tumor
burden because PD was detected 72 days earlier by volumet-
rics. Nevertheless, in this retrospective study we are unable to
answer the question of whether earlier detection of PD affects
overall survival of these patients. Making any definitive
conclusion based on available survival data may be misleading
as the clinical trial that these patients were enrolled on was not
designed to detect differences in survival between volumetrics
and RECIST in a prospective manner. Therefore, a larger sam-
ple size of patients with thymic malignancies assessed with
different measurement criteria in a prospective manner would be
needed to address this important issue.
Previous studies have mimicked three-dimensional tumor
volume measurements with the use of mathematical formulae.7
Our study used software that calculated the tumor volume based
on intensity by Hounsfield units. This is important because
mathematical formulae assume tumor volumes are cylindrical,
which is not the case with thymic tumors. We feel that volu-
metrics may ultimately provide a better assessment of objective
response and occurrence of disease progression in patients with
thymic cancer.
We are aware of a number of limitations to our work.
This is a single-institutional retrospective study, in which
only patients with complete three-dimensional assessment
were included in our analysis; this may lead to selection bias.
Our study has a low number of enrolled patients in either
cohort. In addition, there may be factors that can vary within
and between CT scanners, thus creating differences in the
overall measurement of target lesions. In addition, differences
in measurement may be introduced secondary to patient
positioning or the phase of respiration when comparing re-
staging CT scans.
We feel that conclusions from this study should be used
to stimulate further development into novel methods of de-
tecting and prospectively following tumor burden. Our data
suggest that volumetrics may provide a more accurate repre-
sentation of tumor growth.
FIGURE 2. Overall survival of patients with thymic cancer beginning at dates of RECIST-designated progression (A) and volu-
metrics-designated progression (B). Overall survival of patients with NSCLC beginning at dates of RECIST-designated progres-
sion (C) and volumetrics-designated progression (D). NSCLC, non-small cell lung cancer.
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In conclusion, our findings show that three-dimensional
measurement criteria (volumetrics) may detect PD earlier and
more often than unidimensional measurement criteria
(RECIST) in patients with advanced thymic cancer. Never-
theless, in diseases such as heavily pretreated patients with
metastatic NSCLC undergoing third- or fourth-line therapy,
there is no difference in determination of PD whether one
chooses RECIST or volumetrics measurement methods. The
use of three-dimensional measurement criteria may be more
beneficial in the management of relatively slow growing,
nonspherical tumors such as thymic malignancies. To better
understand, confirm, and validate our findings, a larger pro-
spective study of patients with thymic cancer using volumet-
rics and RECIST for assessment of tumor burden is war-
ranted.
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